Pharmaceutical Research & Drug Development – Page 11

Excipient incompatibility identified late during scale-up preparation – how to redesign formulation strategy

Excipient incompatibility can manifest through various signals that should be monitored closely during the formulation and scale-up processes. Key symptoms include:Click to read the full article.

QbD elements missing during regulatory review – how to redesign formulation strategy

Detecting early signs of missing QbD elements can help avert major crises during regulatory reviews. Key indicators include:Click to read the full article.

Dissolution variability unexplained during IND/NDA filing – CMC risk assessment and mitigation

Identifying symptoms of dissolution variability is the first step in managing potential CMC risks. Symptoms may manifest as:Click to read the full article.

Formulation fails stability targets during scale-up preparation – CMC risk assessment and mitigation

The first signs of formulation stability failure often present as observable quality deviations. Below are the key symptoms to monitor during the scale-up process:Click to read the full article.

Prototype not scalable during scale-up preparation – regulatory expectations for formulation data

Identifying symptoms early is crucial for addressing scale-up issues effectively. Common signals can emerge during prototype development or pilot runs, frequently indicating a potential lack of scalability.Click to read the…

Bioavailability risk flagged during regulatory review – regulatory expectations for formulation data

Identifying early symptoms of bioavailability issues is critical for maintaining compliance and ensuring the efficacy of pharmaceutical formulations. Signals can appear in various forms, including:Click to read the full article.

Prototype not scalable during IND/NDA filing – preventing late-stage reformulation

Recognizing the right signals from your production floor or laboratory is paramount to addressing scalability issues proactively. Here are common symptoms indicative of scalability concerns:Click to read the full article.

Bioavailability risk flagged during scale-up preparation – CMC risk assessment and mitigation

Monitoring for bioavailability risks necessitates keen observation of operational indicators. Here are some key symptoms that may signal potential issues:Click to read the full article.

QbD elements missing during IND/NDA filing – CMC risk assessment and mitigation

In any pharmaceutical manufacturing environment, recognizing early warnings of missing QbD elements is crucial. Symptoms could manifest in various forms:Click to read the full article.

Formulation fails stability targets during IND/NDA filing – regulatory expectations for formulation data

Detecting formulation stability issues can take various forms, often presenting through observable symptoms or laboratory results. Here are the key signals to be aware of:Click to read the full article.

Dissolution variability unexplained during tech transfer – preventing late-stage reformulation

The detection of dissolution variability typically arises from both quantitative data and qualitative observations in the lab or manufacturing floor. Here are the common signals:Click to read the full article.

Excipient incompatibility identified late during early development – preventing late-stage reformulation

Identifying early signals of excipient incompatibility can prevent downstream reformulation challenges. Symptoms may manifest in various forms:Click to read the full article.